Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its... see more

TSXV:SQD.H - Post Discussion

SQI Diagnostics Inc > Four FDA submissions ++
View:
Post by FactFinder1994 on Apr 29, 2021 5:54pm

Four FDA submissions ++

With only a hundred million dollar market cap, success has not even begun to be priced in yet.
 
SQI's multiplex IP's alone are worth more than the current M/C.  

The new "surface tech" is worth more then the current M/C.
 
Each of the four FDA submissions/Approvals are independently worth more that the current M/C.

If not for an under the radar strategy, and the easy manipulation (value suppression) activities as a result, this stock would already be multiples higher than current market cap.

The assets of the company are solid - The only risk is not sharing the story, and therefore allowing the manipulation to continue.
Comment by Lennoc on Apr 30, 2021 6:14pm
Factfinder, I agree. The M/C is too low along with the share price. I have picked up a few shares down here but I would like to see the share price reflect the true value of the company. I sure once we get a few FDA approvals the share price will double.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities